Will CAR T-cell therapy change the treatment landscape for MCL?

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Marion Subklewe, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Will CAR T-cell therapy change the treatment landscape for MCL?

The current standard of care for young, fit patients with mantle cell lymphoma (MCL) is chemotherapy-based induction regimens followed by autologous stem cell transplantation (auto-SCT) for consolidation. In patients with relapsed/refractory (R/R) MCL, second-line treatment involves Bruton's tyrosine kinase inhibitors, such as ibrutinib/acalabrutinib.

There is a subset of R/R patients with high-risk disease that has an overall survival of less than 4 years, and this group is the target for testing treatment with CAR T-cells. Marion Subklewe discusses the results of the ZUMA-2 trial evaluating anti-CD19 CAR T-cells in this subset of patients with R/R MCL.